Hikma Pharmaceuticals’ (HIK) Equal Weight Rating Reaffirmed at Barclays

Share on StockTwits

Barclays reaffirmed their equal weight rating on shares of Hikma Pharmaceuticals (LON:HIK) in a research report sent to investors on Friday morning. They currently have a GBX 1,950 ($25.48) target price on the stock.

A number of other equities research analysts have also commented on the stock. Peel Hunt reaffirmed an add rating on shares of Hikma Pharmaceuticals in a research note on Thursday. Citigroup reaffirmed a buy rating and issued a GBX 2,250 ($29.40) price objective on shares of Hikma Pharmaceuticals in a research note on Tuesday, October 30th. JPMorgan Chase & Co. reaffirmed a neutral rating and issued a GBX 1,050 ($13.72) price objective on shares of Hikma Pharmaceuticals in a research note on Tuesday, August 21st. Finally, Numis Securities reaffirmed a hold rating on shares of Hikma Pharmaceuticals in a research note on Wednesday, August 15th. One research analyst has rated the stock with a sell rating, six have given a hold rating and one has assigned a buy rating to the stock. The stock currently has a consensus rating of Hold and a consensus target price of GBX 1,459 ($19.06).

Shares of LON:HIK traded down GBX 170.50 ($2.23) during trading on Friday, reaching GBX 1,854.50 ($24.23). The stock had a trading volume of 1,517,297 shares, compared to its average volume of 822,138. Hikma Pharmaceuticals has a 52 week low of GBX 814.20 ($10.64) and a 52 week high of GBX 2,346 ($30.65).

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including anti-infective, anaesthetic, central nervous system (CNS), oncology, and pain management, as well as controlled substances and cardiovascular products.

Featured Article: How is Preferred Stock Different from Common Stock?

Analyst Recommendations for Hikma Pharmaceuticals (LON:HIK)

Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

RubleBit  Market Cap Reaches $0.00
RubleBit Market Cap Reaches $0.00
MagicCoin Price Down 34.2% Over Last 7 Days
MagicCoin Price Down 34.2% Over Last 7 Days
Retractable Technologies  Issues Quarterly  Earnings Results
Retractable Technologies Issues Quarterly Earnings Results
Citigroup Lowers Loxo Oncology  Price Target to $213.00
Citigroup Lowers Loxo Oncology Price Target to $213.00
Berry Global Group  Price Target Raised to $59.00 at Citigroup
Berry Global Group Price Target Raised to $59.00 at Citigroup
Walmart  Price Target Increased to $112.00 by Analysts at KeyCorp
Walmart Price Target Increased to $112.00 by Analysts at KeyCorp


Leave a Reply

© 2006-2018 Ticker Report